Gabapentin
Product Images NDC 64725-0138

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64725-0138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0138)

Label for Gabapentin 300 mg capsules in a 30-count package. The label indicates the product is prescription-only and repackaged by TYA Pharmaceuticals, with the original manufacturer listed as Sun Pharm. The label includes a barcode and directs users to see the package insert for dosing information.*

FDA Label Image

Gabapentin-fig01 (Gabapentin Fig01)

A line graph showing weekly mean pain scores over eight weeks comparing placebo and Gabapentin 3600 mg/day. The X-axis represents time in weeks from baseline to week 8, and the Y-axis shows mean pain scores from 0 to 10. The graph indicates a greater reduction in mean pain scores over time for Gabapentin compared to placebo, with notable statistical significance at multiple points.*

FDA Label Image

Gabapentin-fig02 (Gabapentin Fig02)

A line graph showing weekly mean pain scores over 7 weeks for placebo and two doses of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a decrease in pain scores over time compared to placebo.*

FDA Label Image

Gabapentin-fig03 (Gabapentin Fig03)

A bar chart titled 'Proportion of Responders at Endpoint: Controlled PHN Studies' comparing percentage of responders (patients with ≥50% reduction in pain score) between placebo (PBO) and gabapentin (GBP) treatment groups in two studies. Study 1 shows 12% responders with placebo and 29% with GBP 3600. Study 2 shows 14% with placebo and 32% and 34% with GBP 1800 and GBP 2400 doses respectively. Statistical significance is indicated with p-values below 0.01 and 0.001 for gabapentin groups versus placebo.*

FDA Label Image

Gabapentin-fig04 (Gabapentin Fig04)

A scatter plot showing the responder rate difference (%) from placebo for gabapentin by daily dose (mg) across three studies (Study a, Study b, Study c). The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis shows difference in responder rate (percentage). The chart compares data points for each study at various doses with labels 'a', 'b', and 'c' near points to distinguish study results. The caption indicates the data are from adjunctive therapy studies in patients 12 years and older with partial seizures.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of the active ingredient Gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.